Sapient Capital LLC Purchases Shares of 137,329 Elanco Animal Health Incorporated (NYSE:ELAN)

Sapient Capital LLC acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 137,329 shares of the company's stock, valued at approximately $2,046,000.

Other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in shares of Elanco Animal Health by 15.6% during the first quarter. JPMorgan Chase & Co. now owns 355,004 shares of the company's stock valued at $9,262,000 after acquiring an additional 47,881 shares during the period. American Century Companies Inc. raised its holdings in Elanco Animal Health by 11.8% during the 1st quarter. American Century Companies Inc. now owns 32,218 shares of the company's stock worth $841,000 after purchasing an additional 3,396 shares during the last quarter. US Bancorp DE lifted its position in Elanco Animal Health by 17.5% during the 1st quarter. US Bancorp DE now owns 16,263 shares of the company's stock valued at $425,000 after purchasing an additional 2,419 shares during the period. Private Advisor Group LLC acquired a new position in Elanco Animal Health during the 1st quarter valued at about $333,000. Finally, MetLife Investment Management LLC bought a new position in shares of Elanco Animal Health in the 1st quarter valued at about $232,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ELAN shares. The Goldman Sachs Group increased their price objective on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a "sell" rating in a report on Tuesday, February 27th. Stifel Nicolaus upgraded Elanco Animal Health from a "hold" rating to a "buy" rating and raised their price target for the stock from $13.00 to $20.00 in a research report on Friday, January 5th. Morgan Stanley upped their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, February 27th. TheStreet raised Elanco Animal Health from a "d+" rating to a "c-" rating in a research note on Friday, February 23rd. Finally, Barclays boosted their target price on Elanco Animal Health from $18.00 to $19.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Elanco Animal Health presently has an average rating of "Moderate Buy" and an average target price of $16.71.

Elanco Animal Health Stock Down 2.7 %

NYSE ELAN traded down $0.40 during trading hours on Friday, reaching $14.35. 4,431,934 shares of the company's stock were exchanged, compared to its average volume of 4,390,161. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.35 and a current ratio of 2.75. The company has a market capitalization of $7.07 billion, a price-to-earnings ratio of -5.79, a price-to-earnings-growth ratio of 1.55 and a beta of 1.29. The company's 50-day moving average is $15.91 and its two-hundred day moving average is $13.55. Elanco Animal Health Incorporated has a one year low of $7.88 and a one year high of $16.88.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Monday, February 26th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.02). The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. Elanco Animal Health's revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter last year, the company posted $0.19 EPS. On average, analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other Elanco Animal Health news, Director R David Hoover acquired 20,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were bought at an average cost of $16.14 per share, for a total transaction of $322,800.00. Following the completion of the acquisition, the director now directly owns 185,000 shares of the company's stock, valued at $2,985,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 6.40% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.